Atomo Diagnostics Ltd. (AU:AT1)
ASX:AT1
Want to see AU:AT1 full AI Analyst Report?
AT1 Stock Chart & Stats
AU$0.04
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume312.94K
Average Volume (3M)1.80M
Market Cap
AU$16.24M
Enterprise ValueAU$16.17M
Total Cash (Recent Filing)AU$3.51M
Total Debt (Recent Filing)AU$754.39K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary RDT PlatformAtomo's core proprietary rapid diagnostic platform and integrated self-test formats underpin a durable B2B business model. Supplying device designs and consumables to diagnostic brands creates recurring engineering and manufacturing opportunities and supports long-term licensing, customization and scale in point-of-care testing markets.
Low Financial LeverageA very low debt-to-equity ratio provides financial flexibility to fund product development or absorb revenue variability without high interest burdens. This structural balance sheet strength reduces refinancing risk and supports multi-month investment in regulatory approvals, partnerships, or manufacturing scale-up.
Relatively Strong Gross MarginA gross margin near 47% suggests the product design and manufacturing mix can generate healthy unit economics once volumes rise. Sustained mid/high gross margins give room to cover fixed R&D and sales costs and make profitability achievable if revenue growth or scale improves over the medium term.
Bears Say
Declining Revenue TrendRevenue contraction of roughly 10% signals weakening demand or customer delays in adoption. Persistent top-line decline undermines ability to leverage fixed costs and scale manufacturing, strains partner relationships and makes multi-quarter recovery harder without new commercial wins or expanded distribution.
Deep Operating LossesSeverely negative EBIT and net margins indicate structural unprofitability today. Large operating losses erode equity, limit reinvestment capacity, and make it difficult to sustain R&D, regulatory and commercial programs without material improvement in revenue or external capital support.
Negative Cash Flow TrajectoryOngoing negative operating and free cash flows with steep FCF deterioration reduce runway and increase reliance on financing. Poor cash generation constrains investment in scale-up, manufacturing or go-to-market initiatives and raises the risk that growth plans require dilutive funding or costly debt.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$16.24M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 82 days.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Currently, no data Available
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 902,432,860 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AT1 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
-58.40%
Trailing 12-Months
Asset Growth
2.49%
Trailing 12-Months
Company Description
Atomo Diagnostics Ltd.
Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various applications, including COVID-19 detection, HIV screening, pregnancy confirmation, and assessing respiratory conditions.
Technical Analysis
Options Prices
Currently, No data available
---